Advancements in Treatment Management Strategies for EGFR-Mutated NSCLC: Insights from Experts at The University of California Irvine : Episode 5

Amivantamab for Patients With NSCLC and an EGFR Exon 20 Mutation

October 23, 2023

By Misako Nagasaka, MD, PhD
Kristen Neumann, DNP, FNP-C

Opinion

Video

Kristen Neumann, DNP, FNP-C, emphasizes the efficacy of the drug amivantamab for patients with EGFR exon 20 mutations, explaining the challenges of unique skin rashes, but highlighting the importance of teamwork in effectively managing and treating these adverse skin effects.

EP: 1.Managing Treatment-Related Rashes in Patients With EGFR-Mutated NSCLC

EP: 2.Managing Treatment-Related Diarrhea in Patients With EGFR-Mutated NSCLC

EP: 3.Implementing Dose Reductions and Dose Holds in Patients With EGFR-Mutated NSCLC Receiving TKIs

EP: 4.Multidisciplinary Management of Treatment-Related Adverse Events in Patients With EGFR-Mutated NSCLC

EP: 5.Amivantamab for Patients With NSCLC and an EGFR Exon 20 Mutation

EP: 6.Educating Patients and Clinical Staff on Infusion-Related Adverse Reactions Seen With Amivantamab in NSCLC With EGFR Exon 20 Mutations

EP: 7.Future Perspectives in the Treatment and Management of Patients With EGFR-Mutated NSCLC

EP: 8.Approaches to Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)

EP: 9.EGFR Mutations in Patients With NSCLC

EP: 10.Adverse Effect Management in Non–Small Cell Lung Cancer Treatment

EP: 11.Patient Case Presentation: A 59-Year-Old Man With EGFR-Mutant NSCLC

EP: 12.The Future of Treatment for EGFR TKI Resistance in EGFR-Mutant NSCLC

EP: 13.Multidisciplinary Care, Approval Updates, and Future Research in NSCLC

EP: 14.Treatment Approaches for Patients With EGFR-Mutant NSCLC

EP: 15.Common Adverse Events Seen With EGFR TKIs in EGFR-Mutant NSCLC

EP: 16.Approaches to Managing Patients With EGFR-Mutant NSCLC and EGFR TKI Resistance

EP: 17.Patient Case Presentation: A 69-Year-Old Man With NSCLC With EGFR Exon 20 Insertion Mutations

EP: 18.Management Strategies for Adverse Events Seen With Amivantamab in NSCLC With EGFR Exon 20 Insertion Mutations

EP: 19.The Future of Treatment for NSCLC With EGFR Exon 20 Insertion Mutations

EP: 20.Unmet Needs and Future Perspectives in NSCLC Treatment

EP: 21.New Lung Cancer Treatment Options Combine Neoadjuvant and Adjuvant Therapies

Recent Videos

6 experts are featured in this series.

6 experts are featured in this series.

6 experts are featured in this series.

6 experts are featured in this series.

Related Content

Zipalertinib Meets Primary ORR End Point in EGFR exon 20 NSCLC

Zipalertinib Meets Primary ORR End Point in EGFR exon 20 NSCLC

January 29th 2025

Full results from the phase 1/2 REZILIENT1 trial evaluating zipalertinib in NSCLC will be shared at a future medical conference.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc

September 16th 2024

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

A single-arm phase 2 study assessed local consolidative therapy regimens in patients with oligometastatic stage IV non–small cell lung carcinoma.

Local Consolidative Therapy Combo May Extend Survival in Stage IV NSCLC

Roman Fabbricatore

January 22nd 2025

A single-arm phase 2 study assessed local consolidative therapy regimens in patients with oligometastatic stage IV non–small cell lung carcinoma.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Results from a Chinese phase 1 trial reveal that anlotinib plus EGFR-TKIs demonstrated manageable toxicity in NSCLC pre-treated with EGFR-TKIs.

Anlotinib Prolongs EGFR-TKI Clinical Benefit in Advanced NSCLC

Roman Fabbricatore

January 21st 2025

Results from a Chinese phase 1 trial reveal that anlotinib plus EGFR-TKIs demonstrated manageable toxicity in NSCLC pre-treated with EGFR-TKIs.

Seattle-based Clinicians on Effective Treatment Combos in EGFR-Mutated NSCLC

Seattle-based Clinicians on Effective Treatment Combos in EGFR-Mutated NSCLC

January 17th 2025

A panel of experts met to discuss the best treatment options for patients with EGFR or TP53-mutated non–small cell lung cancer.

Related Content

Zipalertinib Meets Primary ORR End Point in EGFR exon 20 NSCLC

Zipalertinib Meets Primary ORR End Point in EGFR exon 20 NSCLC

January 29th 2025

Full results from the phase 1/2 REZILIENT1 trial evaluating zipalertinib in NSCLC will be shared at a future medical conference.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc

September 16th 2024

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

A single-arm phase 2 study assessed local consolidative therapy regimens in patients with oligometastatic stage IV non–small cell lung carcinoma.

Local Consolidative Therapy Combo May Extend Survival in Stage IV NSCLC

Roman Fabbricatore

January 22nd 2025

A single-arm phase 2 study assessed local consolidative therapy regimens in patients with oligometastatic stage IV non–small cell lung carcinoma.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Results from a Chinese phase 1 trial reveal that anlotinib plus EGFR-TKIs demonstrated manageable toxicity in NSCLC pre-treated with EGFR-TKIs.

Anlotinib Prolongs EGFR-TKI Clinical Benefit in Advanced NSCLC

Roman Fabbricatore

January 21st 2025

Results from a Chinese phase 1 trial reveal that anlotinib plus EGFR-TKIs demonstrated manageable toxicity in NSCLC pre-treated with EGFR-TKIs.

Seattle-based Clinicians on Effective Treatment Combos in EGFR-Mutated NSCLC

Seattle-based Clinicians on Effective Treatment Combos in EGFR-Mutated NSCLC

January 17th 2025

A panel of experts met to discuss the best treatment options for patients with EGFR or TP53-mutated non–small cell lung cancer.

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.